title: [Biomarkers in inflammatory bowel diseases].
abstract: Fecal calprotectine is of interest for diagnosis of IBD at the beginning. CRP and fecal calprotectine are predictive of long-term response in patients treated by anti-TNF therapy. Trough levels of anti-TNF are associated to clinical remission and mucosal healing. Detectable antibodies to anti-TNF are associated with lower response to treatment. Interventional studies are waiting before optimization of treatment in function of biomarkers. Trough levels of anti-TNF help to modify our treatment (optimization or de-escalation).
authors.affiliation: CHU de Saint-Étienne, hôpital Nord, service de gastro-entérologie, 42277 Saint-Priest-en-Jarez, France. Electronic address: xavier.roblin@chu-st-etienne.fr.
authors.forename: Xavier
authors.initials: X
authors.lastname: Roblin
authors.affiliation: CHU de Saint-Étienne, hôpital Nord, service de chirurgie digestive, 42277 Saint-Priest-en-Jarez, France.
authors.forename: Alaric
authors.initials: A
authors.lastname: Cavaille
authors.affiliation: CHU de Saint-Étienne, hôpital Nord, service de gastro-entérologie, 42277 Saint-Priest-en-Jarez, France.
authors.forename: Léa
authors.initials: L
authors.lastname: Clavel
authors.affiliation: CHU de Saint-Étienne, hôpital Nord, immunopharmacologie, 42277 Saint-Priest-en-Jarez, France.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Paul
mesh_terms: D015415:Biomarkers / Q000032:analysis*; D002097:C-Reactive Protein / Q000378:metabolism; D005243:Feces / Q000737:chemistry; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D039841:Leukocyte L1 Antigen Complex / Q000032:analysis; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D015415:Biomarkers; D039841:Leukocyte L1 Antigen Complex; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein